Get the Stockscreener App
7.56
7.85%
0.55
Eikon Therapeutics Inc stock is traded at $7.56, with a volume of 557.98K.
It is up +7.85% in the last 24 hours and down -20.34% over the past month.
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
See More
Previous Close:
$7.01
Open:
$7.01
24h Volume:
557.98K
Relative Volume:
1.03
Market Cap:
$409.49M
Revenue:
Net Income/Loss:
P/E Ratio:
-1.6871
EPS:
-4.481
Net Cash Flow:
1W Performance:
+0.80%
1M Performance:
-20.34%
6M Performance:
-30.26%
1Y Performance:
+0.00%
1-Day Range:
$7.01
$7.69
1-Week Range:
$6.4482
$7.82
52-Week Range:
$6.4482
$17.40
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Name
Eikon Therapeutics Inc
Sector
Industry
Phone
341-777-0566
Address
230 HARRIET TUBMAN WAY, MILLBRAE
Compare EIKN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
7.56 | 409.49M | 0 | 0 | 0 | -4.481 |
VRTX
Vertex Pharmaceuticals Inc
|
508.51 | 128.89B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.37 | 95.17B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.72 | 82.33B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
855.36 | 53.79B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.56 | 42.37B | 5.76B | 514.49M | 1.10B | 4.4813 |
Eikon Therapeutics Inc Stock (EIKN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Initiated | BofA Securities | Buy |
| Mar-02-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-26 | Initiated | JP Morgan | Overweight |
| Mar-02-26 | Initiated | Mizuho | Outperform |
| Mar-02-26 | Initiated | Morgan Stanley | Overweight |
| Feb-26-26 | Initiated | Wedbush | Underperform |
View All
Eikon Therapeutics Inc Stock (EIKN) Latest News
A subsidiary holds the shares behind Abu Dhabi Investment Authority’s Eikon Therapeutics (EIKN) stake. - stocktitan.net
Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering - Yahoo Finance
Dear Future Electra Therapeutics Stock Fans, Mark Your Calendars for Sept. 18 - Yahoo Finance
Eikon Therapeutics at Cantor conference: selective cancer drugs advance By Investing.com - Investing.com India
Eikon Therapeutics at Cantor conference: selective cancer drugs advance By Investing.com - Investing.com Canada
Eikon Therapeutics at Cantor conference: selective cancer drugs advance By Investing.com - Investing.com UK
Inhibrx stock, Eikon stock rise on insider buying (INBX:NASDAQ) - Seeking Alpha
Eikon Therapeutics (NASDAQ:EIKN) Trading Up 6.9% After Insider Buying Activity - MarketBeat
Eikon Therapeutics (NASDAQ:EIKN) Raised to Strong-Buy at Mizuho - MarketBeat
Group Iv Gp Lp Column Buys 89,200 Shares of Eikon Therapeutics (NASDAQ:EIKN) Stock - MarketBeat
Open-market insider buy at Eikon Therapeutics (EIKN) - Stock Titan
Eikon Therapeutics names CP Chang as chief scientific officer By Investing.com - Investing.com South Africa
Eikon Therapeutics names CP Chang as chief scientific officer By Investing.com - Investing.com Nigeria
Eikon Therapeutics names CP Chang as chief scientific officer By Investing.com - Investing.com Canada
Eikon Therapeutics Appoints CP Chang as Executive Vice President and Chief Scientific Officer - Quiver Quantitative
Eikon Therapeutics names CP Chang as chief scientific officer By Investing.com - Investing.com UK
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer - finance.yahoo.com
A Bristol Myers Squibb research leader joins Eikon as science chief - Stock Titan
BlackRock Inc. Buys 962,046 Shares of Eikon Therapeutics, Inc. $EIKN - MarketBeat
EDGAR Filing Documents for 0001193125-26-349936 - sec.gov
Eikon Therapeutics to Participate in Investor Conferences in September 2026 - The Manila Times
Eikon Therapeutics to Participate in Investor Conferences in September 2026 - Moomoo
Eikon (EIKN) Financial Update: EPS Misses Its Estimate on the Day; After Results: The Stock Ends Up 12.46% in the Latest SessionProfit Announcement - vinanet.vn
Eikon Therapeutics, Inc. (NASDAQ:EIKN) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004 - Yahoo Finance
Cantor Fitzgerald reiterates Overweight on Eikon stock - Investing.com
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald - Sahm
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald - The Manila Times
An oncology expert will discuss PARP drugs in four cancers Aug. 20 - Stock Titan
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald - Yahoo Finance
EIKN Q1 2026 Earnings: Deeper-than-Expected Loss but Shares Rally 6.97%Energy Earnings Report - vinanet.vn
Morgan Stanley Maintains Eikon Therapeutics(EIKN.US) With Buy Rating, Maintains Target Price $32 - Moomoo
$Eikon Therapeutics (EIKN.US)$ - Moomoo
Eikon Therapeutics adds Merck chemistry head to advisory board By Investing.com - Investing.com Nigeria
Form 8K EIKON THERAPEUTICS For: 14 August By Investing.com - Investing.com Australia
Eikon Therapeutics Updates Corporate Presentation, Files Form 8-K Under Regulation FD - kalkinemedia.com
Eikon Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.6, Implies 138% Upside - TradingView
Possible Turnaround For Eikon Therapeutics Insiders, Still Down US$852k - simplywall.st
Possible Turnaround For Eikon Therapeutics Insiders, Still Down US$852k - simplywall.st
Form 8K EIKON THERAPEUTICS For: 14 August By Investing.com - Investing.com Nigeria
Form 8K EIKON THERAPEUTICS For: 14 August By Investing.com - Investing.com Canada
Form 8K EIKON THERAPEUTICS For: 14 August By Investing.com - Investing.com India
Form 8K EIKON THERAPEUTICS For: 14 August By Investing.com - Investing.com UK
Eikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and to the Compensation Committee - marketscreener.com
Eikon Therapeutics, Inc. 2Q 2026: Net income $(88.4)M, EPS $(1.63) — 10-Q Summary - TradingView
Eikon Therapeutics (EIKN) reports $171.4M first-half loss and $531M cash - Stock Titan
Eikon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates - Yahoo Finance
FMR LLC Expands Eikon Therapeutics Inc (EIKN) Stake Despite Post-IPO Slide - GuruFocus
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma - The Manila Times
Eikon Therapeutics Inc Stock (EIKN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eikon Therapeutics Inc Stock (EIKN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Column Group IV GP, LP | 10% Owner |
Feb 06 '26 |
Buy |
18.00 |
2,117,760 |
38,119,680 |
4,312,139 |
| Foresite Capital Management IV | 10% Owner |
Feb 04 '26 |
Buy |
18.00 |
55,555 |
999,990 |
1,318,983 |
| FRAZIER KENNETH C | Director |
Feb 04 '26 |
Buy |
18.00 |
111,111 |
1,999,998 |
111,111 |
| Wolfe Josh | Director |
Feb 04 '26 |
Buy |
18.00 |
277,776 |
4,999,968 |
138,888 |
| Lux Venture Partners V, LLC | 10% Owner |
Feb 04 '26 |
Buy |
18.00 |
277,776 |
4,999,968 |
138,888 |
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):